The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa

Sheba Medical Center

Status

Completed

Conditions

Retinitis Pigmentosa

Treatments

Dietary Supplement: Alga Dunaliella Bardawill

Dietary Supplement: Alga Dunaliella Bardawil

Other: Sugar pill

Study type

Interventional

Funder types

Other

Identifiers

NCT01256697

SHEBA -08-5086-YR-CTIL

Details and patient eligibility

About

Retinitis pigmentosa is a genetically determined disease consisting of progressive centripetal retinal degeneration starting in the rods outer segments. Its prevalence is 1:4000 people and is the fourth most common blinding disease in Israel in 2004 [7% of all blindness]. The investigators tried to treat a non-progressive form of the disease [Fundus Albipunctatus] by oral therapy of the food supplement made from alga Dunaliella bardawil composed of approximately 50% 9-cis β-carotene. The alga Dunaliella bardawil accumulates high concentration of β -carotene when grown under appropriate conditions. The β -carotene of the alga is composed of approximately 50% of all-trans - β carotene and 50% 9-cis β -carotene.

The 9-cis β -carotene has shown to be a precursor of 9-cis retinoic acid both in-vitro in human intestinal mucosa and in-vivo in a ferret, perfuse with 9-cis b-carotene. The night vision, as measured objectively by electroretinography (ERG) more than doubled in six patients tested. The visual field was also improved significantly.

Enrollment

34 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent to participate in the study.
Men or women aged 18 years or older.
Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa

Exclusion criteria

Current smokers.
Current use of Vitamin A/ beta carotene supplements.
Active arterial disease within 3 months of study entry such as unstable angina, myocardial infarction, transient ischemic attack (TIA), stroke, and coronary artery bypass graft (CABG) surgery.
History of malignancy, except basal or squamous cell skin carcinoma.
Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception.
Uncontrolled hypertension defined as either resting diastolic blood pressure of >95mmHg (taken from the mean of 3 readings) or resting systolic blood Pressure of > 180 mmHg.
History of alcohol abuse or drug abuse, or both.
Patient plans to engage in vigorous exercise or an aggressive diet regimen.
Uncontrolled endocrine or metabolic disease.
Participation in another investigational drug study within 4 weeks of entry into this study.
Serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
Subject whose hormone replacement therapy (HRT) or oral contraceptive therapy (OCT) was initiated within the 3 month prior to enrollment.